Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial

Clicks: 409
ID: 116602
2003
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
The efficacy and safety of high-dose intravenous polyspecific immunoglobulin G (IVIG) as adjunctive therapy in streptococcal toxic shock syndrome (STSS) were evaluated in a multicenter, randomized, double-blind, placebo-controlled trial. The trial was prematurely terminated because of slow patient r …
Reference Key
j2003clinicalintravenous Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Darenberg J;Ihendyane N;Sjölin J;Aufwerber E;Haidl S;Follin P;Andersson J;Norrby-Teglund A; ;;
Journal Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Year 2003
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/12884156
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine treatment outcome research support non-u.s. gov't adult female male aged middle aged 80 and over Clinical Trial Randomized Controlled Trial Double-Blind Method Multicenter Study immunoglobulins immunoglobulin g / therapeutic use* intravenous shock streptococcal infections / mortality pmid:12884156 doi:10.1086/376630 jessica darenberg nahla ihendyane streptig study group septic / microbiology septic / mortality septic / therapy* streptococcal infections / therapy*

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.